公开(公告)号：WO2013008233A1

公开(公告)日：2013-01-17

申请号：PCT/IL2012/050186

申请日：2012-05-23

Applicant: GREAT ASPIRATIONS LTD. ,  DIAMANT, Valery ,  LOTAN, Chaim ,  DANENBERG, Haim

Inventor： DIAMANT, Valery ,  LOTAN, Chaim ,  DANENBERG, Haim

IPC: A61B17/221

CPC classification number: A61B17/221 ,  A61B2017/00862 ,  A61B2017/00867 ,  A61B2017/00871 ,  A61B2017/22039 ,  A61B2017/2215

Abstract: A retrieval apparatus for entrapping and retaining an object located in a body for its extraction therefrom is described. The retrieval apparatus includes a snare and a snare control assembly. The snare has a proximal section and a distal section, and comprises a plurality of filaments extending from a proximal end of the proximal section towards the distal section, and then returning to the proximal end to form a plurality of loops. In the deployed state, the loops are interlaced to each other within the proximal section and are free and not interleaved within the distal section. Segments of the filaments of the distal section are bent with respect to segments of the filaments of the proximal section such that the retrieval snare in the contracted state forms a hollow cavity extending from the distal section towards the proximal section.

Abstract translation: 描述了用于捕获和保持位于身体中的物体以从其中提取的取回装置。 检索装置包括圈套和圈套控制组件。 圈套具有近端部分和远侧部分，并且包括从近端部分的近端向远侧部分延伸的多个细丝，然后返回到近端以形成多个环。 在展开状态下，环在近端部分内彼此交织，并且在远端部分内是自由的并且不交错的。 远端部分的细丝的部分相对于近端部分的细丝的部分弯曲，使得处于收缩状态的取出圈套形成从远侧部分向近侧部分延伸的中空腔。

公开(公告)号：WO2006087722A1

公开(公告)日：2006-08-24

申请号：PCT/IL2006/000209

申请日：2006-02-16

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ,  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  GOLOMB, Gershon ,  DANENBERG, Haim ,  SCHACHTER, Morey

Inventor： GOLOMB, Gershon ,  DANENBERG, Haim ,  SCHACHTER, Morey

IPC: A61K31/00 ,  A61K31/663 ,  A61P15/00

CPC classification number: A61K31/00 ,  A61K31/663

Abstract: A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.

Abstract translation: 公开了一种治疗子宫内膜异位症的新方法。 该方法包括向有需要的女性受试者施用治疗有效量的包含能够抑制女性受试者的吞噬细胞的药剂的颗粒。

公开(公告)号：WO2005002545A8

公开(公告)日：2006-02-16

申请号：PCT/US2004020487

申请日：2004-06-24

Applicant: BIOREST LTD ,  RICHTER YORAM ,  EDELMAN ELAZER R ,  GOLOMB GERSHON ,  DANENBERG HAIM D

Inventor： EDELMAN ELAZER R ,  GOLOMB GERSHON ,  DANENBERG HAIM D

IPC: A61K31/663 ,  A61K9/127

CPC classification number: A61K31/663

Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acture coronary syndrome such as unstable angina and acute myocardial infarction.

Abstract translation: 本发明涉及设计用于治疗或治疗急性冠状动脉综合征，特别是不稳定性心绞痛和急性心肌梗塞的方法和组合物。 本发明的方法包括施用有效量的含有一种或多种治疗剂的制剂，其特异性降低或抑制吞噬细胞的活性和/或消除或减少吞噬细胞的量，包括但不限于巨噬细胞 和单核细胞。 制剂专门针对吞噬细胞。 本发明还提供了含有本发明的一种或多种治疗剂的制剂的药物组合物，用于给予目前患有或最近患有冠状动脉综合征如不稳定型心绞痛和急性心肌梗死的受试者。

公开(公告)号：WO2007012947A3

公开(公告)日：2008-12-31

申请号：PCT/IB2006002028

申请日：2006-07-25

Applicant: BIOREST LTD ,  RICHTER YORAM ,  EDELMAN ELAZER R ,  GOLOMB GERSHON ,  DANENBERG HAIM D

Inventor： RICHTER YORAM ,  EDELMAN ELAZER R ,  GOLOMB GERSHON ,  DANENBERG HAIM D

IPC: A01N43/00 ,  A61K31/33 ,  A61K31/663

CPC classification number: A61K31/337 ,  A61K9/127 ,  A61K31/282 ,  A61K31/365 ,  A61K31/436 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/56 ,  A61K31/60 ,  A61K31/616 ,  A61K31/663 ,  A61K31/7072 ,  A61K33/00 ,  A61K33/04 ,  A61K33/24

Abstract: The present invention relates to methods and compositions designed for the prevention, reduction, treatment or management of ischemia-reperfusion injury. The methods of the invention comprise the administration of an effective amount of a therapeutic formulation containing one or more active compounds in a formulation which specifically decreases or inhibits the activity of and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and/or monocytes. In preferred embodiments, the active compound is a bisphosphonate. The invention also provides pharmaceutical compositions of therapeutic formulations for administration to subjects currently suffering from, having recently suffered, or at risk of suffering from an ischemia-reperfusion injury.

Abstract translation: 本发明涉及设计用于预防，减少，治疗或治疗缺血再灌注损伤的方法和组合物。 本发明的方法包括在制剂中施用有效量的含有一种或多种活性化合物的治疗剂型，其特异性降低或抑制吞噬细胞的活性和/或消除或减少吞噬细胞的量，包括但不限于 ，巨噬细胞和/或单核细胞。 在优选的实施方案中，活性化合物是双膦酸盐。 本发明还提供了用于给予目前患有，最近遭受或有遭受缺血再灌注损伤风险的受试者的治疗制剂的药物组合物。

公开(公告)号：WO2005013948A3

公开(公告)日：2006-03-02

申请号：PCT/US2004020536

申请日：2004-06-24

Applicant: BIOREST LTD ,  EDELMAN ELAZER R ,  GOLOMB GERSHON ,  DANENBERG HAIM D

Inventor： EDELMAN ELAZER R ,  GOLOMB GERSHON ,  DANENBERG HAIM D

IPC: A61K9/127 ,  A61K9/51 ,  A61K31/66 ,  A61K31/663 ,  A61K31/675

CPC classification number: A61K31/663 ,  A61K9/127 ,  A61K9/51 ,  A61K31/66 ,  A61K31/675

Abstract: A method of treating an acute myocardial infarction by administering to an individual an effective amount of a formulation which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction. The formulation comprises an agent which is an intracellular inhibitor that is released within the targeted phagocytic cells, specifically macrophage/monocytes, and inhibits and/or destroys the macrophages and/or monocytes, thereby reducing the final zone of infarct and improving cardiac repair and myocardial remodeling. Since macrophages and monocytes possess the unique ability to phagocytose large bodies, the agent is formulated into a specific size such that it can enter cells primarily via phagocytosis. Thus, the specifically sized formulation selectively targets monocytes/macrophages. The formulation may comprise an encapsulated agent, an embedded agent or a particulate agent, wherein the formulation is of a specific size, such that it can enter cells primarily via phagocytosis. The formulation is preferably in the size range of 0.03-1.0 microns.

Abstract translation: 一种治疗急性心肌梗塞的方法，其通过向个体施用有效量的抑制和/或消除吞噬细胞的特异性高的制剂，由此抑制在急性心肌梗死期间和之后发生的炎性反应。 该制剂包含作为靶向吞噬细胞特异性巨噬细胞/单核细胞释放的细胞内抑制剂的药剂，并且抑制和/或破坏巨噬细胞和/或单核细胞，从而减少梗塞的最后区域并改善心脏修复和心肌 重塑。 由于巨噬细胞和单核细胞具有吞噬大体的独特能力，所以将药物配制成特定的大小，使得其主要通过吞噬作用进入细胞。 因此，特定尺寸的制剂选择性靶向单核细胞/巨噬细胞。 制剂可以包括包封的试剂，嵌入剂或颗粒剂，其中所述制剂具有特定尺寸，使得其可以主要通过吞噬作用进入细胞。 制剂优选在0.03-1.0微米的尺寸范围内。

公开(公告)号：WO2005013948A2

公开(公告)日：2005-02-17

申请号：PCT/US2004/020536

申请日：2004-06-24

Applicant: BIOREST LTD. ,  EDELMAN, Elazer, R. ,  GOLOMB, Gershon ,  DANENBERG, Haim, D.

Inventor： EDELMAN, Elazer, R. ,  GOLOMB, Gershon ,  DANENBERG, Haim, D.

IPC: A61K31/00

CPC classification number: A61K31/663 ,  A61K9/127 ,  A61K9/51 ,  A61K31/66 ,  A61K31/675

Abstract: A method of treating an acute myocardial infarction by administering to an individual an effective amount of a formulation which inhibits and/or depletes phagocytic cells with high specificity, thereby suppressing the inflammatory response that occurs during and following acute myocardial infarction. The formulation comprises an agent which is an intracellular inhibitor that is released within the targeted phagocytic cells, specifically macrophage/monocytes, and inhibits and/or destroys the macrophages and/or monocytes, thereby reducing the final zone of infarct and improving cardiac repair and myocardial remodeling. Since macrophages and monocytes possess the unique ability to phagocytose large bodies, the agent is formulated into a specific size such that it can enter cells primarily via phagocytosis. Thus, the specifically sized formulation selectively targets monocytes/macrophages. The formulation may comprise an encapsulated agent, an embedded agent or a particulate agent, wherein the formulation is of a specific size, such that it can enter cells primarily via phagocytosis. The formulation is preferably in the size range of 0.03-1.0 microns.

Abstract translation: 一种治疗急性心肌梗塞的方法，其通过向个体施用有效量的抑制和/或消除吞噬细胞的特异性高的制剂，由此抑制在急性心肌梗死期间和之后发生的炎性反应。 该制剂包含作为靶向吞噬细胞特异性巨噬细胞/单核细胞释放的细胞内抑制剂的药剂，并且抑制和/或破坏巨噬细胞和/或单核细胞，从而减少梗塞的最后区域并改善心脏修复和心肌 重塑。 由于巨噬细胞和单核细胞具有吞噬大体的独特能力，所以将药物配制成特定的大小，使得其主要通过吞噬作用进入细胞。 因此，特定尺寸的制剂选择性靶向单核细胞/巨噬细胞。 制剂可以包括包封的试剂，嵌入剂或颗粒剂，其中所述制剂具有特定尺寸，使得其可以主要通过吞噬作用进入细胞。 制剂优选在0.03-1.0微米的尺寸范围内。

公开(公告)号：WO2011039738A1

公开(公告)日：2011-04-07

申请号：PCT/IL2010/000604

申请日：2010-07-28

Applicant: CARDIONITI ,  DIAMANT, Valery ,  DANENBERG, Haim ,  LOTAN, Chaim ,  YASKO, Nadezda

Inventor： DIAMANT, Valery ,  DANENBERG, Haim ,  LOTAN, Chaim ,  YASKO, Nadezda

IPC: A61M29/02 ,  A61B17/3207

CPC classification number: A61B17/22032 ,  A61B17/320725 ,  A61B90/39 ,  A61B2017/00526 ,  A61B2017/00539 ,  A61B2017/00853 ,  A61B2017/00893 ,  A61B2017/22061 ,  A61F2/958 ,  A61M25/0045 ,  A61M25/0053 ,  A61M25/1034 ,  A61M25/104 ,  A61M2025/0057 ,  A61M2025/105 ,  Y10T29/49826

Abstract: A cutting balloon assembly (10) and a method for fabrication of the assembly is described. The cutting balloon assembly comprises a delivery catheter (11), an expandable balloon (12) mounted on the catheter distal end, and a scoring mesh (13) disposed around the expandable balloon. The scoring mesh comprises interlacing filaments (131) that extend from a mesh proximal end towards a mesh distal end, form distal filament loops (135) at said mesh distal end, and then return to the mesh proximal end. At least a part of the interlacing filaments forms one or more permanent links with neighboring filaments between the mesh proximal end and the mesh distal end.

Abstract translation: 描述了一种切割气囊组件（10）和该组件的制造方法。 切割气囊组件包括输送导管（11），安装在导管远端上的可膨胀气囊（12）和设置在可膨胀气囊周围的刻痕网（13）。 刻痕网包括从网状近端朝向网孔远端延伸的交织细丝（131），在所述网孔远端形成远端丝线环（135），然后返回到网状近端。 交织丝的至少一部分在网状物近端和网状物远端之间形成与相邻细丝的一个或多个永久性连接。

公开(公告)号：WO2007012947A2

公开(公告)日：2007-02-01

申请号：PCT/IB2006/002028

申请日：2006-07-25

Applicant: BIOREST LTD. ,  RICHTER, Yoram ,  EDELMAN, Elazer, R. ,  GOLOMB, Gershon ,  DANENBERG, Haim, D.

Inventor： RICHTER, Yoram ,  EDELMAN, Elazer, R. ,  GOLOMB, Gershon ,  DANENBERG, Haim, D.

IPC: A61K31/47

CPC classification number: A61K31/337 ,  A61K9/127 ,  A61K31/282 ,  A61K31/365 ,  A61K31/436 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/56 ,  A61K31/60 ,  A61K31/616 ,  A61K31/663 ,  A61K31/7072 ,  A61K33/00 ,  A61K33/04 ,  A61K33/24

Abstract: The present invention relates to methods and compositions designed for the prevention, reduction, treatment or management of ischemia-reperfusion injury. The methods of the invention comprise the administration of an effective amount of a therapeutic formulation containing one or more active compounds in a formulation which specifically decreases or inhibits the activity of and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and/or monocytes. In preferred embodiments, the active compound is a bisphosphonate. The invention also provides pharmaceutical compositions of therapeutic formulations for administration to subjects currently suffering from, having recently suffered, or at risk of suffering from an ischemia-reperfusion injury.

Abstract translation: 本发明涉及设计用于预防，减少，治疗或治疗缺血再灌注损伤的方法和组合物。 本发明的方法包括在制剂中施用有效量的含有一种或多种活性化合物的治疗制剂，所述制剂特异性降低或抑制吞噬细胞的活性和/或消除或减少吞噬细胞的量，包括但不限于 ，巨噬细胞和/或单核细胞。 在优选的实施方案中，活性化合物是双膦酸盐。 本发明还提供了用于给予目前患有，最近遭受或有遭受缺血再灌注损伤风险的受试者的治疗制剂的药物组合物。

公开(公告)号：WO2005002545A1

公开(公告)日：2005-01-13

申请号：PCT/US2004/020487

申请日：2004-06-24

Applicant: BIOREST LTD. ,  RICHTER, Yoram ,  EDELMAN, Elazer, R. ,  GOLOMB, Gershon ,  DANENBERG, Haim, D.

Inventor： EDELMAN, Elazer, R. ,  GOLOMB, Gershon ,  DANENBERG, Haim, D.

IPC: A61K9/127

CPC classification number: A61K31/663

Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acture coronary syndrome such as unstable angina and acute myocardial infarction.

Abstract translation: 本发明涉及设计用于治疗或治疗急性冠状动脉综合征，特别是不稳定性心绞痛和急性心肌梗塞的方法和组合物。 本发明的方法包括施用有效量的含有一种或多种治疗剂的制剂，其特异性降低或抑制吞噬细胞的活性和/或消除或减少吞噬细胞的量，包括但不限于巨噬细胞 和单核细胞。 制剂专门针对吞噬细胞。 本发明还提供了含有本发明的一种或多种治疗剂的制剂的药物组合物，用于给予目前患有或最近患有冠状动脉综合征如不稳定型心绞痛和急性心肌梗死的受试者。

公开(公告)号：WO2003089568A2

公开(公告)日：2003-10-30

申请号：PCT/IB2003/001437

申请日：2003-04-16

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  GOLOMB, Gershon ,  DANENBERG, Haim

Inventor： GOLOMB, Gershon ,  DANENBERG, Haim

IPC: C12N

CPC classification number: A61K9/5153 ,  A61K9/127 ,  A61K31/00 ,  A61K31/66 ,  A61K31/663 ,  A61K31/675 ,  A61K33/24 ,  Y10S514/824 ,  Y10S514/951

Abstract: A method of treating or preventing restenosis by administering to an individual an effective amount of an active compound which depletes and/or inhibits blood monocytes or macrophages thereby treating restenosis. A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active compound which depletes and/or inhibits blood monocytes or macrophages thereby treating restenosis. The cytokines and growth factors include, but are not limited to interleukin 1-β, matrix metalloproteinase-2, and platelet-derived growth factor β (PDGFβ). The active compound may be administered directly, encapsulated in a carrier particle, or in a particulate dosage form. The compound may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the compound which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active compound. The compound includes any intra-cellular toxin which depletes and/or inhibits blood monocytes or macrophages, such as, for example, a bisphosphonate.

Abstract translation: 通过向个体施用有效量的消耗和/或抑制血液单核细胞或巨噬细胞从而治疗再狭窄的活性化合物来治疗或预防再狭窄的方法。 通过向个体施用有效量的消耗和/或抑制血液单核细胞或巨噬细胞从而治疗再狭窄的活性化合物来抑制与血管再狭窄相关的细胞因子或生长因子的活性或产生的方法。 细胞因子和生长因子包括但不限于白细胞介素1-β，基质金属蛋白酶-2和血小板衍生生长因子β（PDGFβ）。 活性化合物可以直接给药，包封在载体颗粒中或颗粒剂型中。 该化合物可被包封，嵌入或吸附在颗粒内，均匀分散在聚合物基质中，吸附在颗粒表面上，或以任何这些形式的组合。 颗粒包括脂质体或惰性聚合物颗粒，如微胶囊，纳米胶囊，纳米颗粒，纳米球或微粒。 颗粒包括未被包封，包埋或吸附在聚合物颗粒内的任何悬浮或分散形式的化合物。 颗粒包括活性化合物的悬浮或分散的胶体，聚集体，絮凝物，不溶性盐和不溶性复合物。 该化合物包括消耗和/或抑制血液单核细胞或巨噬细胞的任何细胞内毒素，例如二膦酸盐。